Proteasome inhibitor PS-341 is one of the most promising novel agents against multiple myeloma (MM). We have previously shown that PS-341 inhibits IL-6 triggered phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 (also known as p42/44 mitogen-activated protein kinases) in MM cells. In this study, we further examined whether clinically achievable concentrations of PS-341 could inhibit IL-6 triggered signaling cascades in MM. We found that PS-341 inhibited not only ERK, but also signal transducers and activators of transcription (STAT) 3 as well as Akt phosphorylation. Since gp130 (CD130) dimerizes and is phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be involved in PS-341-induced blockade of signaling cascades mediating MM cell growth, survival, and drug resistance in the bone marrow (BM) microenvironment. In this study, we first demonstrate that PS-341 induces downregulation of gp130 in a time-and dose-dependent manner in vitro, prior to MM cell death. Conversely, downregulation of gp130 is completely abrogated by the pan-caspase inhibitor Z-VAD-FMK, suggesting that downregulation of gp130 is mediated via caspase activation. Z-VAD-FMK also abrogates the inhibitory effect of PS-341 on IL-6-triggered signaling cascades. Importantly, we demonstrate that phosphorylation of ERK, STAT3, and Akt in MM.1S cells induced by either exogenous IL-6 or by binding of MM cells to BM stromal cells is abrogated by PS-341. These studies, therefore, define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment.
Introduction
Multiple myeloma (MM) is a B-cell malignancy that affects 14 400 new individuals annually in the United States, with 50 000 total patients, and remains incurable despite conventional and high-dose therapies. In the bone marrow (BM) microenvironment, the interaction of MM cells with BM stromal cells (SCs) triggers signaling cascades mediating MM cell proliferation, survival, drug resistance, and migration. In addition, MM cell adhesion to bone marrow stromal cells (BMSCs) upregulates transcription and secretion of IL-6 in BMSCs via a nuclear factor (NF)-kB-dependent pathway (Chauhan et al., 1996; Hideshima et al., 2002b) . IL-6-induced upstream signaling is mediated via activation of gp130/CD130 (Taga et al., 1989; Matsuda et al., 1994 Matsuda et al., , 1995 Nishimoto et al., 1994; Ogata et al., 1997a; Kurth et al., 1999) and downstream cascades promoting growth, survival, and drug resistance in MM cells in the BM milieu.
We and others have demonstrated that IL-6 induces growth (Hallek et al., 1998; Kawano et al., 1988; Klein et al., 1989) and antiapoptosis (Lichtenstein et al., 1995; Chauhan et al., 1997a-c) in human MM cells, and characterized the signaling cascades mediating these effects. For example, IL-6 induces proliferation of MM cells via activation of the Ras/Raf/MEK/ERK signaling pathway , whereas IL-6-induced JAK/STAT3 signaling promotes MM cell survival by modulating Bcl-XL and/or Mcl-1 protein expression (Catlett-Falcone et al., 1999; Puthier et al., 1999a, b; Wei et al., 2001; Semenov et al., 2002) . IL-6 also activates phosphatidylinositol-3 kinase (PI3-K) and downstream protein kinase Akt in MM cells (Tu et al., 2000; Hideshima et al., 2001b) . In addition, we and others have shown that IL-6 protects against Dex-induced apoptosis (Hardin et al., 1994; Lichtenstein et al., 1995; Chauhan et al., 1997c; Ogawa et al., 2000) . Specifically, our studies show that Dex-induced apoptosis in MM cells is mediated via related adhesion focal tyrosine kinase (RAFTK) activation (Chauhan et al., 1999) ; conversely, IL-6 confers protection against Dex-induced apoptosis via activation of SH2 domain containing protein tyrosine kinase SHP2, which binds and dephosphorylates RAFTK . Importantly, our recent study demonstrates that IL-6 abrogates Dex-induced apoptosis via inactivation of caspase-9 (Hideshima et al., 2001b) .
In contrast, we have demonstrated that proteasome inhibitor PS-341 directly induces apoptosis, even in MM cell lines and patients MM cells which are resistant to conventional therapies, by activation of caspase-8, caspase-9, and caspase-3 Hideshima et al., 2001c Hideshima et al., , 2003b Mitsiades et al., 2002b) ; and can overcome the antiapoptotic effects of IL-6 or of MM cell adherence to BMSCs (Hideshima et al., 2001c) . PS-341 also inhibits human MM cell growth and associated angiogenesis, as well as prolonging survival, in a murine SCID mouse model (LeBlanc et al., 2002) . Most importantly, PS-341 has achieved remarkable responses, even complete responses, in a Phase II clinical trial treating patients with relapsed MM refractory to conventional therapies, with an acceptable toxicity profile . This drug therefore represents a new treatment paradigm in MM targeting not only the tumor cell, but also the MM cellhost interaction and the BM milieu, to overcome drug resistance and improve patient outcome.
In our previous study, PS-341 demonstrated the abrogation of ERK activation triggered by both exogenous IL-6 and BMSC adherence in MM.1S cells (Hideshima et al., 2001c) . In this report, we further define a novel mechanism whereby PS-341 can overcome IL-6-triggered MM cell growth, survival, and drug resistance effects in the BM milieu. We demonstrate that PS-341 induces downregulation of gp130 prior to MM cell death, thereby abrogating IL-6-mediated downstream signaling cascades. Our results therefore demonstrate that PS-341-induced downregulation of gp130 blocks both IL-6-and cell adhesion-induced MM cell growth, survival, and drug resistance in the BM microenvironment.
Results

PS-341 inhibits IL-6 triggered signaling cascades
Since we have demonstrated that pretreatment with PS-341 completely abrogated ERK phosphorylation triggered by IL-6 in MM.1S cells (Hideshima et al., 2001c) , we further examined whether clinically achievable concentrations of PS-341 could also inhibit IL-6-triggered signaling cascades in MM cells. MM.1S cells were cultured in the presence of PS-341 (20 and 40 nM) prior to IL-6 (100 ng/ml) stimulation. IL-6 induced significant phosphorylation of ERK1/2, Akt and STAT3 in MM.1S cells cultured in DMSO control media; however, PS-341 pretreatment inhibits IL-6-induced phosphorylation of these kinases and transcription factor in a dose-dependent manner, without alteration of protein expression (Figure 1a for 8 h, and cells were then stimulated with IL-6 (100 ng/ml) for 10 and 20 min. Whole cell lysates were subjected to Western blotting to assess the phosphorylation and protein expression of STAT3, ERK1/2, and Akt using specific Abs against these kinases. (b) MM.1S cells were pretreated with PS-341 (20 nM) for 8 h, and cells were then stimulated with IGF-1 (100 ng/ml) for 10 and 20 min. Whole cell lysates were subjected to Western blotting to assess the phosphorylation and protein expression of Akt using specific Abs gp130 downregulation by caspase in myeloma T Hideshima et al whether the extracellular domain of gp130, assessed using flow cytometry, was similarly altered by PS-341 treatment. As expected, PS-341 induced no (U266 and patient MM cells) or only minimal (MM.1S cells) downregulation of extracellular gp130 expression ( Figure 3a) . We further examined gp130 expression using an Ab in Western blotting that recognizes its extracellular domain. Increased expression of lower molecular weight protein was observed after 6 h PS-341 treatment (Dgp130, Figure 3b ). Importantly, cell viability, assessed by trypan blue exclusion, was not altered by PS-341 treatment under these conditions.
Downregulation of gp130 by PS-341 is dependent on caspase activation
Since we have demonstrated that PS-341 induces activation of caspase-8 and caspase-9, followed by caspase-3 cleavage (Hideshima et al., 2001c (Hideshima et al., , 2003b Mitsiades et al., 2002b) , we next hypothesized that the cytoplasmic domain of gp130, like other proteins, might also be cleaved or downregulated via caspase activation. We first confirmed that both caspase-3 and caspase-8 cleavage triggered by PS-341 in MM.1S cells (20 nM for 6, 8, and 10 h), and showed that PS-341 induces caspase cleavage in a time-dependent manner ( Figure 4a ). To confirm whether downregulation of gp130 by PS-341 is caspase-dependent, we next cultured MM.1S cells with PS-341 (20 nM for 8 h), in the presence or absence of caspase inhibitors. Although either caspase-8 inhibitor Z-IETD-FMK or caspase-9 inhibitor Z-LEHD-FMK only partially inhibited the effect of PS-341, the pancaspase inhibitor Z-VAD-FMK completely abrogates downregulation of gp130 induced by PS-341 (Figure 4b ), suggesting that caspase-3 may mediate this event. This result is consistent with our previous report that PS-341 induces both caspase-8 and caspase-9 cleavage, followed by caspase-3 cleavage Hideshima et al., 2003b) . Having shown that downregulation Z-VAD-FMK abrogates downregulation of gp130 and inhibition of IL-6 triggered signaling by PS-341
Since Z-VAD-FMK abrogates PS-341-induced downregulation of gp130 assessed by Western blotting, we further examined whether inhibition of IL-6-triggered intracellular signaling cascades by PS-341 is also abrogated by Z-VAD-FMK. Inhibition of ERK1/2 or STAT3 phosphorylation by PS-341 was not observed in the presence of Z-VAD-FMK (Figure 5a ). Taken together, our results suggest that PS-341 overcomes the antiapoptotic effect of IL-6, at least in part, by downregulating gp130 protein expression.
To further define the biological significance of IL-6 in modulating the effect of PS-341 treatment, we first incubated MM.1S cells with PS-341 (5 and 10 nM) for 5 h to activate caspases. Cells were then treated with IL-6, in the presence or absence of Z-VAD-FMK. PS-341 triggered 50% (5 nM) and 75% (10 nM) inhibition of [ 3 H]thymidine uptake, and either Z-VAD-FMK or IL-6 only partially abrogated this effect. Importantly, however, the combination of IL-6 and Z-VAD-FMK significantly (Po0.01) blocked the inhibitory effect of PS-341 in MM.1S cells (Figure 5b ).
PS-341 inhibits paracrine signaling cascades in BMSC cultures
We have previously shown that adherence of MM cells to BMSCs induces transcription and secretion of IL-6 in the BM microenvironment (Chauhan et al., 1996; Hideshima et al., 2002b) , which mediates MM cell growth, drug resistance, and antiapoptosis. We therefore further examined whether PS-341 inhibits signaling cascades in MM.1S cells triggered by MM cell binding to BMSCs. To avoid any direct effect of PS-341 on BMSCs, MM.1S cells were pretreated with DMSO control media or PS-341 (40 nM for 4 h), washed, and then cultured for 4 h without PS-341, prior to culture with BMSCs. The concentration of IL-6 in BMSC culture supernatant, determined by ELISA, was 3.1 ng/ ml. We first demonstrated that ERK, STAT3, and Akt phosphorylation is induced in MM.1S cells adherent to BMSCs (Figure 6 ). In contrast, pretreatment of MM.1S cells with PS-341 significantly inhibited phosphorylation of these kinases in MM.1S cells triggered by MM cell binding to BMSCs. Taken together, these effects of PS-341 indicate that it enhances PS-341-induced apoptosis by inhibiting IL-6 signaling even in the BM microenvironment.
Discussion
We have recently reported that the proteasome inhibitor PS-341 can overcome drug resistance of MM cells in preclinical in vitro (Hideshima et al., 2001c (Hideshima et al., , 2003b Mitsiades et al., 2002b) and in vivo animal studies (LeBlanc et al., 2002) . In particular, it directly induces apoptosis of MM cells, abrogates binding of MM cells to BM (Hideshima et al., 2001a) , and inhibits angiogenesis (LeBlanc et al., 2002) as well as transcription and secretion of cytokines in the BM milieu (Hideshima et al., 2001c) . Most importantly, this agent achieved remarkable responses, including complete responses, in phase II clinical trials in relapsed and refractory MM Figure 5 Inhibition of IL-6 triggered signaling by PS-341 is abrogated by Z-VAD-FMK. (a) MM.1S cell were incubated with PS-341 (20 nM) for 8 h in the presence or absence of Z-VAD-FMK. Cells were then stimulated with IL-6 (100 ng/ml) for 10 min. Whole cell lysates were subjected to Western blotting to assess phosphorylation and/or protein expression of gp130, STAT3, and ERK1/2 using specific Abs. (b) MM.1S cells were incubated with PS-341 (20 nM) for 5 h. Cells were then treated with DMSO control ('), IL-6 (50 ng/ml, ), Z-VAD-FMK (25 mM, ), or IL-6 þ Z-VAD-FMK (&). The cells were then pulsed with [ 3 H]thymidine (1 mCi/ well) during the last 6 h of 24 h cultures. All experiments were performed in quadruplicate Figure 6 PS-341 inhibits BMSC-induced signaling cascades. MM.1S cells were pretreated with PS-341 (40 nM for 4 h). Cells were then washed three times with media and incubated for 4 h without PS-341 prior to addition to BMSC-coated plates and culture for 30 and 60 min. MM.1S cells were harvested, and whole cell lysates were subjected to Western blotting to assess phosphorylation and protein expression of ERK1/2, STAT3, and Akt using specific Abs against these kinases gp130 downregulation by caspase in myeloma T Hideshima et al . PS-341-induced MM cell death is mediated by activation of caspases (Hideshima et al., 2001c (Hideshima et al., , 2003b Mitsiades et al., 2002b) . PS-341 inhibits ERK phosphorylation in MM cells and related paracrine MM cell growth in the BM milieu triggered both by tumor cell binding to BMSCs and by IL-6 (Hideshima et al., 2001c) . It also blocks the protective effect of IL-6 against Dex-induced apoptosis. These data may account, at least in part, for the efficacy of PS-341 against MM cells in the BM microenvironment (Hideshima and .
MM cell lines and MM patient cells are responsive to IL-6 stimulation both in vitro and in vivo, and biologic sequelae of IL-6 in MM pathogenesis have been extensively studied. Specifically IL-6 is a potent survival and antiapoptotic factor in MM via activation of multiple signaling cascades. IL-6 binds to IL-6R/gp80, which induces phosphorylation and homodimerization of gp130 (Matsuda et al., 1994 (Matsuda et al., , 1995 Nishimoto et al., 1994; Taga et al., 1989; Kurth et al., 1999) . Downstream of gp130 activation, IL-6 triggers Ras/Raf/MEK/p42/44 MAPK-mediated proliferation ; activates JAK/STAT3 signaling promoting MM cell survival by regulating Bcl-XL and/or Mcl-1 protein expression (Catlett-Falcone et al., 1999; Puthier et al., 1999a, b; Semenov et al., 2002) ; and activates PI3-K/Akt signaling, thereby promoting antiapoptosis and drug resistance in MM cells (Tu et al., 2000; Hideshima et al., 2001b) . Importantly, these signaling cascades triggered by IL-6 may reduce the effectiveness of conventional chemotherapeutic agents against MM cells in BM milieu.
Although we have demonstrated that PS-341 inhibited ERK phosphorylation triggered by IL-6, the concentration of PS-341 (5 mM for 1 h treatment) (Hideshima et al., 2001c) , is 100 times higher than is clinically achievable, and we could not exclude the possibility of direct toxicity of PS-341 against ERK signaling pathways triggered by IL-6. In this study, we therefore examined the effect of PS-341-on IL-6-induced signaling cascades at a clinically achievable concentration of PS-341 in MM. Specifically, we pretreated MM.1S cells with PS-341 (20 nM) prior to stimulation with exogenous IL-6 (100 ng/ml), and characterized phosphorylation of ERK, STAT3, or Akt (Hideshima et al., 2001b . Surprisingly, phosphorylation of ERK, STAT3, and Akt was inhibited by PS-341 pretreatment in a dosedependent manner. This result demonstrates that PS-341 inhibits IL-6 triggered downstream signaling cascades, and allows us to hypothesize that PS-341 may alter phosphorylation and/or downregulation of gp130. As expected, PS-341 demonstrated time-and dose-dependent downregulation of gp130 in MM.1S, U266 and RPMI8226 cell lines. Moreover, gp130 downregulation was also induced by PS-341 in freshly isolated patient MM cells. Importantly, the concentrations of PS-341 used in our study (20 nM) are clinically achievable. We further examined the expression of the extracellular domain of gp130 by flow cytometric analysis and Western blotting, as well as the cytoplasmic domain of gp130 by immunoblotting. Although the cytoplasmic domain of gp130 is completely downregulated after PS-341 treatment, the extracellular domain of gp130 is preserved. These results demonstrate that PS-341-induced intracytoplasmic downregulation of gp130.
Most recently, we have demonstrated that PS-341 triggers caspase activation and subsequent cleavage of DNA-PKCs (Hideshima et al., 2003b) . We therefore further hypothesized that PS-341 may similarly induce downregulation of gp130 via caspase activation. PS-341-induced gp130 downregulation and inhibition of IL-6 signaling cascades was completely blocked by the pancaspase inhibitor, suggesting that PS-341-induced gp130 downregulation is mediated by caspase-3 or its downstream molecules. Our ongoing studies are delineating the mechanisms of downregulation of gp130 and determining whether other agents which induce caspase-3 activation also induce downregulation of gp130 in MM in vitro.
The BM milieu plays a critical role in MM cell pathogenesis. BMSCs secrete cytokines including IL-6 (Uchiyama et al., 1993; Chauhan et al., 1996; Hideshima et al., 2001a Hideshima et al., , c, 2002b Hideshima and Anderson, 2002) , insulin-like growth factor-1 (Mitsiades et al., 2002a) , vascular endothelial growth factor Podar et al., 2001; Hideshima et al., 2003b) , and stromal cell-derived factor-1a , which promote MM cell growth, antiapoptosis, and/or migration. Among these cytokines, IL-6 plays a central role in MM cell survival. Moreover, MM cell adherence to BMSCs upregulates NF-kB-dependent transcription and secretion of IL-6 in BMSCs (Uchiyama et al., 1993; Chauhan et al., 1996; Gupta et al., 2001; Hideshima et al., 2001a Hideshima et al., , c, 2002b . Our prior studies have shown that PS-341 inhibits NF-kB activation and thereby inhibits constitutive and MM cell adhesioninduced IL-6 transcription and secretion in BMSCs (Hideshima et al., 2001a, c) . The present study shows that PS-341 further inhibits IL-6-triggered and MM cell adhesion-induced signaling cascades mediating MM cell growth and survival by inducing downregulation of gp130, suggesting that it can block both cytokine protection and bioactivity. Finally, gp130 is the common receptor b-subunit of other gp130 family member cytokines, including oncostatin M (OSM) and leukemia inhibitory factor (LIF). Since these cytokines also induce downstream signaling cascades via gp130 activation (Nishimoto et al., 1994; Chauhan et al., 1995; Juge-Morineau et al., 1995) , PS-341 may also abrogate OSM-and/or LIF-mediated signaling in MM.
In conclusion, we have shown that PS-341 induced sequential activation of caspase-8 or caspase-9, followed by activation of caspase-3 and downregulation of gp130. Downregulation of gp130 abrogates IL-6-mediated downstream signaling cascades promoting MM cell proliferation, survival, and drug resistance by inhibiting IL-6-induced phosphorylation of ERK, STAT3, and Akt, as well as their downstream targets including Bcl-XL, Mcl-1, Bad, and caspase-9 (Figure 7) . In addition to inducing MM cell apoptosis, abrogating binding of MM cells to BMSCs, and inhibiting transcription and secretion of cytokines in the BM milieu, the current gp130 downregulation by caspase in myeloma T Hideshima et al study therefore shows that PS-341 can also inhibit cytokine-induced signaling. Our ongoing studies are focused on identifying the caspase cleavage sites within the gp130 cytoplasmic domain by generic studies using gp130 mutants. These studies therefore define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokineinduced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment.
Materials and methods
MM-derived cell lines and patient MM cells
MM.1S (wild-type p53; Hideshima et al., 2000) human MM cell line was kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). RPMI8226 and U266 human MM cells were obtained from American Type Culture Collection (Rockville, MD, USA). All MM cell lines were cultured in RPMI-1640 containing 10% fetal bovine serum (FBS, Sigma Chemical Co., St Louis, MO, USA), 2 mM Lglutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO, Grand Island, NY, USA). Patient MM cells were purified from patient BM aspirates by negative selection using anti-CD2, CD14, CD33, CD41, CD45RA, and CD66b Abs (RosetteSep separation system, StemCell Technologies, Vancouver, Canada) . The purity of MM cells was 495%, as confirmed by flow cytometric analysis using anti-CD138 Ab (BD Pharmingen, San Diego, CA, USA). Immunoblotting MM cell lines and patient MM cells cultured with PS-341 were harvested, washed, and lysed in lysis buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM NaF, 2 mM Na 3 V 4 , 1 mM PMSF, 5 mg/ml leupeptine, and 5 mg/ml aprotinin. Protein lysates (60 mg) were then subjected to Western blotting, as in prior studies (Hideshima et al., 2001c . The Abs used in Western blotting were: anti-gp130, which recognized either the cytoplasmic domain (Upstate Biotechnology, Lake Placid, NY, USA) or extracellular domain (R&D Systems, Minneapolis, MN, USA); anticaspase-3 (BD Pharmingen, San Diego, CA, USA); -phospho-p42/44 MAPK, -p42/44 MAPK, -phospho-STAT3, and -STAT3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); as well as anti-phospho-Akt and -Akt (Cell Signaling, Beverly, MA, USA). To analyse the inhibitory effect of PS-341-on IL-6-mediated signaling due to downregulation of gp130, MM.1S cells were cultured with PS-341 (0-40 nM) for 8 h prior to stimulation with IL-6 (100 ng/ml) for 10 and 20 min.
BMSC cultures
Flow cytometric analysis
For detection of extracellular gp130 (CD130) expression, MM.1S and U266 MM cell lines, as well as patient MM cells, were cultured with PS-341 (10-40 nM), harvested, washed with PBS, and stained with mouse IgG isotype control or PEconjugated mouse anti-human CD130 Ab (BD Pharmingen, San Diego, CA, USA). gp130 expression was analysed using an Epics (Coulter Immunology, Hialeah, FL, USA) flow cytometer, as in prior studies (Hideshima et al., 2001a .
Cell proliferation assay
Cell proliferation was assessed by [ 3 H]thymidine (Perkin Elmer, Boston, MA, USA) uptake, as in our previous studies (Hideshima et al., , 2001c . To determine the functional significance of IL-6, MM.1S cells were incubated with PS-341 (5 and 10 nM) for 5 h prior to stimulation by IL-6 (50 ng/ml), in the presence or absence of Z-VAD-FMK (25 mM). Cells were then pulsed with [ 3 H]thymidine (1 mCi/well) during the last 6 h of 24 h cultures. All experiments were performed in quadruplicate. Figure 7 Model for caspase-induced downregulation of gp130, which sensitizes MM cells to apoptosis in the BM microenvironment. IL-6 activates gp130 and mediates MM cell proliferation, drug resistance, and antiapoptosis via ERK, STAT3, and Akt signaling cascades, respectively, as well as their downstream targets including Bcl-XL, Mcl-1, Bad, and caspase-9. Apoptotic stimuli induce caspase-8 and/or caspase-9 followed by activation of caspase-3, which subsequently cleave gp130. Downregulation of gp130 blocks IL-6-mediated signaling cascades, thereby sensitizing MM cells to apoptotic stimuli in the BM microenvironment
